Press Release
Basel, December 3, 2009 - Novartis announced today that the European Commission (EC) has approved Onbrez Breezhaler (QAB149 or indacaterol) in both 150 mcg and 300 mcg doses as a new once-d...
PharmiWeb,
Thu Dec 03 01:40:06 PST 2009
• Found on Yahoo! News
New Data On Highly Effective Treatment For Chronic Rhinosinusitis With Nasal Polyp...
OptiNose is pleased to announce the publication of results from its Phase II clinical study investigating the efficacy and tolerability of its novel, intranasal drug/device product for the ...
Medical News Today,
Wed Dec 02 07:10:05 PST 2009
• Found on Yahoo! News
Topix.net
360,000 news channels, from Autos to your ZIP code.
• Found on Topix News
New data on highly effective treatment for chronic rhinosinusitis with nasal polyp...
( WFD Ventures ) OptiNose is pleased to announce the publication of results from its Phase II clinical study investigating the efficacy and tolerability of its novel, intranasal drug/device...
EurekAlert!,
Tue Dec 01 09:42:52 PST 2009
• Found on Yahoo! News
Eurand Launches ZENPEPTM (Pancrelipase) Delayed-Release Capsules
Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, announced the commercial availability of ZENPEP
Medical News Today,
Tue Dec 01 03:41:47 PST 2009
• Found on Yahoo! News
Tacio: Understanding osteoporosis
Health 101 read more
Sun Star,
Mon Nov 30 06:51:20 PST 2009
• Found on Yahoo! News
Eurand Launches ZENPEP(TM) (Pancrelipase) Delayed-Release Capsules
First and Only FDA-Approved Pancreatic Enzyme Product Clinically Proven in Patients as Young as One Year Old
Marketwire,
Mon Nov 30 04:03:46 PST 2009
• Found on Yahoo! News
Eurand Launches ZENPEP(TM) (Pancrelipase) Delayed-Release Capsules
PHILADELPHIA, PA--(Marketwire - 11/30/09) - Eurand N.V. (NASDAQ: EURX - News ), a global specialty pharmaceutical company, today announced the commercial availability of ZENPEP(TM) (pancrel...
Marketwire via Yahoo! Finance,
Mon Nov 30 04:00:00 PST 2009
• Found on Yahoo! News